UK - Pharmaceutical giant GlaxoSmithKline is conducting a review that could result in executive contracts being cut from two years to 12 months.
The move follows chief executive Jean-Pierre Garnier’s announcement that he is prepared to give up parts of his controversial £22m package if he loses his job.
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
